Seminar, Hosted by NIH Wednesday Afternoon Lecture Series (WALS)
Encouraging Results and Updates in Personalized Neoantigen Targeting Vaccines
Dana-Farber Cancer Institute; Harvard Medical School
- Oncology, Immunology and
Abstract
Multiple lines of evidence have demonstrated tumor neoantigens to be an important class of immunogenic tumor antigens, motivating the development of personalized cancer neoantigen targeting approaches. Neoantigens arise from amino acid changes encoded by somatic mutations in tumor cells and can bind to and be presented by a patient's own HLA molecules. The field has moved beyond the first wave of proof-of-concept studies demonstrating the safety, feasibility and high immunogenicity of these personalized vaccines. The lecture addresses the challenges now facing the approach: discovering and optimizing the selection of antigens to target, the delivery approach, and extending personalized neoantigen vaccines to a broader array of cancer settings, in the context of tumor heterogeneity.